For people living with narcolepsy, no amount of sleep alleviates the feeling of being tired. While most people are either awake or asleep, narcolepsy feels as if you're never really in either state.

There are two types of narcolepsy, and both cause EDS. Most people with Type 1 (with cataplexy — the sudden loss of muscle tone explained above) have low levels of the brain hormone hypocretin ...

In addition to excessive daytime sleepiness, up to 60% of narcolepsy cases include cataplexy, which is a sudden loss of muscle control. When patients experience intense emotion, either positive or ...

Get inspired by a weekly roundup on living well, made simple. Sign up for CNN’s Life, But Better newsletter for information ...

Samelisant (SUVNG-3031) is under development for the treatment of narcolepsy with and without cataplexy and cognitive disorders. The drug candidate is administered orally in the form of tablet. The ...

About LUMRYZ™ (sodium oxybate) for extended-release oral suspension LUMRYZ is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime ...

Axsome Therapeutics has announced that its investigational narcolepsy therapy has met the primary endpoint in a Phase III trial. AXS-12 (reboxetine), the norepinephrine reuptake inhibitor and ...

Gelastic cataplexy is a sudden loss of muscle tone without loss of consciousness triggered by laughter. It’s a characteristic sign of a rare genetic disease called Niemann Pick disease type C.

AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) Statistically significant improvement in cognition compared to placebo ...

Statistically significant improvement in cognition compared to placebo (p=0.011, NSAQ) Statistically significant improvement in narcolepsy overall compared to placebo (p=0.024, PGI-C) Cataplexy ...